Loading clinical trials...

Esketamine Combined With PRF of DRG for Postherpetic Neuralgia | Clinical Trials | Clareo Health

NOT_YET_RECRUITINGNA

Esketamine Combined With PRF of DRG for Postherpetic Neuralgia

Intravenous Infusion of Esketamine in Combination With Pulsed Radiofrequency of Dorsal Root Ganglion for Postherpetic Neuralgia

NCT06914193•Beijing Tiantan Hospital

View on ClinicalTrials.gov

Summary

This trial's primary objective is to compare the analgesic efficacy of esketamine in combination with pulsed radiofrequency (PRF) of dorsal root ganglion(DRG) against that of PRF monotherapy in patients with postherpetic neuralgia(PHN).

Detailed Description

This study aims to determine whether the addition of esketamine to the PRF of DRG regimen can relieve pain in PHN patients. By doing so, the research endeavors to identify a rapid, effective, and safe treatment approach for refractory PHN patients

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Ages more than 18 years;
•2. Pain persisting for over three months following the onset of the herpes zoster skin rash;
•3. Lesions located in in the unilateral cervical, thoracic, and lumbosacral segments;
•4. Having an average pain score of at least 4 on a Numeric Rating Scale (NRS, 0 = no pain, 10= worst possible pain)； Planned to perform CT-guided PRF treatment of the Dorsal root ganglion（DRG）

Exclusion Criteria

•1. Obstructive sleep apnoea syndrome;
•2. Those who receive other more invasive treatments, such as radiofrequency thermocoagulation (RFT) of DRG.
•3. A history of systemic immune diseases, organ transplantation, or cancers;
•4. A history of severe cardiopulmonary, hepatic, renal dysfunction or coagulation function disorder;
•5. A history of schizophrenia, epilepsy, or myasthenia gravis, delirium;
•6. Comorbid hyperthyroidism or phaeochromocytoma;
•7. Recent history of drug abuse;
•8. Having contraindications to esketamine;
•9. Communication difficulties.
•10. Women who are preparing for pregnancy, in the pregnancy or lactation period.

Locations (1)

Beijing Tiantan Hospital

Beijing, Beijing Municipality, China

Key Dates

Start Date

April 1, 2025

Primary Completion Date

July 1, 2026

Completion Date

October 1, 2026

Last Updated

April 9, 2025

Enrollment

186

ESTIMATED participants

Conditions

Postherpetic Neuralgia

Interventions

esketamine+PRF treatment group

DRUG

PRF treatment group

DRUG

Contacts

Fang Luo

CONTACT

+86 13611326978 13611326978@163.com

The Effectiveness of Ultra-Sound Guided Erector Spinae Block With Betamethasone for Management of Truncal Chronic Post Herpetic Neuralgia.

NCT07000409

Postherpetic NeuralgiaChronic Pain+3 more

View study

RECRUITINGNA

Esketamine Combined Pregabalin and Duloxetine for Postherpetic Neuralgia

NCT06896994

Postherpetic Neuralgia

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 9, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Esketamine Combined With PRF of DRG for Postherpetic Neuralgia

Inclusion Criteria

Exclusion Criteria

The Effectiveness of Ultra-Sound Guided Erector Spinae Block With Betamethasone for Management of Truncal Chronic Post Herpetic Neuralgia.

Esketamine Combined Pregabalin and Duloxetine for Postherpetic Neuralgia

Relationship Between Serum Vitamin D Levels and Postherpetic Neuralgia.

Dorsal Root Ganglion Stimulation in Postherpetic Neuropathy

Predictors of Success After Intercostal Nerve Radiofrequency Treatment for Intercostal Neuralgia

Safety and Efficacy Study of KAI-1678 to Treat Pain in Subjects With Postherpetic Neuralgia